Kim et al present a protocol that is the basis for clinical-grade mDA neuron production and preclinical safety and efficacy studies. Read more.
Related News
Press Releases
BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan
December 17, 2025
Press Releases